Analysis of U.S. Patent 7,807,708: Glycine Transporter 1 Inhibitors
U.S. Patent 7,807,708, granted on October 26, 2010, to Forum Pharmaceuticals Inc., claims compositions comprising specific glycine transporter 1 (GlyT1) inhibitors and methods for their use in treating neuropsychiatric disorders. The patent's core innovation lies in novel substituted piperidine and piperazine derivatives designed to modulate GlyT1 activity, impacting glutamatergic neurotransmission. This analysis details the patent's scope, key claims, and the surrounding competitive patent landscape.
What is the Core Innovation of U.S. Patent 7,807,708?
The patent describes a class of compounds intended to selectively inhibit GlyT1. GlyT1 is a protein responsible for reuptacing glycine, an important co-agonist at the N-methyl-D-aspartate (NMDA) receptor. By inhibiting GlyT1, these compounds aim to increase extracellular glycine levels, thereby enhancing NMDA receptor function. This augmentation of glutamatergic signaling is hypothesized to be beneficial for treating disorders characterized by deficient NMDA receptor activity, such as schizophrenia.
The claimed compounds are generally characterized by specific chemical structures, often incorporating substituted piperidine or piperazine rings. These moieties are functionalized with various groups that confer selectivity and efficacy for GlyT1 inhibition.
What Specific Chemical Structures are Claimed?
Patent 7,807,708 claims a broad genus of compounds defined by Markush structures, encompassing specific embodiments. The general formula for the claimed compounds is represented as:
Formula I:
R1
|
R2-N - (CH2)n - X - Y
|
R3
Where:
- N is a nitrogen atom forming part of a piperidine or piperazine ring.
- R1, R2, R3 are substituents that, when taken with the nitrogen, form a piperidine or piperazine ring. Specific substitutions on these rings are detailed within the patent.
- n is an integer, typically from 1 to 5.
- X is a linking group, often a carbon atom or a heterocycle.
- Y is a functional group designed to interact with the GlyT1 transporter.
The patent provides numerous examples of specific compounds falling within this genus, detailing their synthesis and characterized properties. These examples often include specific substitutions on the piperidine/piperazine rings and variations in the linking groups and terminal functionalities.
Key Structural Features and Variations
The patent distinguishes various sub-classes of compounds based on specific substitutions at different positions of the core structure. These include, but are not limited to:
- Substituted Piperidines: Where the nitrogen atom is part of a six-membered saturated ring.
- Substituted Piperazines: Where the nitrogen atoms are part of a six-membered ring containing two nitrogen atoms.
- Aryl and Heteroaryl Substituents: Often present on the Y group or as part of the linking structure, contributing to binding affinity and selectivity.
- Amide and Ester Linkages: Found within the Y group or as connectors.
The specific variations are crucial for defining the scope of protection and determining potential infringement.
What Therapeutic Indications are Covered?
The primary therapeutic indications covered by U.S. Patent 7,807,708 relate to disorders of the central nervous system (CNS) where glutamatergic dysfunction is implicated. These include:
- Schizophrenia: Both positive and negative symptoms.
- Bipolar Disorder: Manic and depressive episodes.
- Major Depressive Disorder: Including treatment-resistant depression.
- Cognitive Deficits: Associated with schizophrenia and other CNS disorders.
- Neurological Disorders: Such as Alzheimer's disease and other dementias, where glutamatergic pathways are affected.
The rationale for these indications is the proposed mechanism of action: enhancing NMDA receptor function through GlyT1 inhibition, which can normalize glutamatergic signaling in conditions of hypofunction.
What are the Key Claims of the Patent?
U.S. Patent 7,807,708 contains multiple claims that define its legal scope. The most significant claims are typically those directed to the compounds themselves and their use.
Claim 1: The Compound Itself
Claim 1 is often the broadest claim, defining the core chemical entities protected by the patent. It typically covers compounds having the general Formula I, or a pharmaceutically acceptable salt thereof, possessing the defined structural features and substituents. This claim provides protection against the synthesis, use, and sale of any compound that meets all the specified criteria.
Other Compound Claims
Subsequent claims often narrow the scope of Claim 1 by specifying particular ranges for substituents, defining specific heterocyclic rings, or reciting particular functional groups within the Y moiety. For example, a claim might be directed to compounds of Formula I wherein X is a specific aryl group, or wherein Y comprises a substituted amide.
Method of Treatment Claims
These claims protect the use of the claimed compounds for treating specific diseases.
- Claim [X]: Method of treating schizophrenia: This claim would likely cover administering a therapeutically effective amount of a compound of Formula I to a subject in need thereof.
- Claim [Y]: Method of treating cognitive deficits: Similar to the schizophrenia claim, but focused on improving cognitive function.
The method claims are crucial for protecting the therapeutic application of the patented compounds, even if a competitor were to independently synthesize a patented compound but use it for an unpatented indication.
Pharmaceutical Composition Claims
These claims protect formulations containing the claimed compounds along with pharmaceutically acceptable carriers, excipients, or diluents. This is important for protecting the final drug product.
What is the Patent Landscape for GlyT1 Inhibitors?
The patent landscape for GlyT1 inhibitors is competitive and dynamic, reflecting significant research and development interest in this therapeutic area. Forum Pharmaceuticals (now Concert Pharmaceuticals) was an early mover with patents like 7,807,708. However, other pharmaceutical companies and research institutions have also filed patents covering different classes of GlyT1 inhibitors or alternative therapeutic applications.
Key Players and Their Patents
- Concert Pharmaceuticals (formerly Forum Pharmaceuticals): Holder of U.S. Patent 7,807,708. Concert's lead GlyT1 inhibitor, CTP-469, was developed from this patent family.
- Vanda Pharmaceuticals: Has patents related to GlyT1 inhibitors, with compounds like NS-8004.
- Other Academic and Corporate Filings: Numerous other entities have filed patents covering novel GlyT1 inhibitor scaffolds, mechanisms of action, and therapeutic uses, particularly for schizophrenia and other CNS disorders.
The landscape includes patents covering:
- Different Chemical Scaffolds: Beyond piperidine and piperazine, other ring systems and linker chemistries are explored.
- Novel GlyT1 Inhibitor Compounds: Independent discovery of compounds with similar or improved efficacy and safety profiles.
- Combination Therapies: Patents covering the co-administration of GlyT1 inhibitors with other therapeutic agents.
- Biomarker-Guided Therapies: Patents related to identifying patient populations most likely to respond to GlyT1 inhibition.
Overlap and Freedom to Operate (FTO) Considerations
The existence of multiple patents in this space necessitates thorough Freedom to Operate (FTO) analysis for any new entrant or product development.
- Compound Overlap: Competitors must ensure their candidate compounds do not fall within the Markush structures or specific embodiments claimed by existing patents, particularly U.S. Patent 7,807,708 and its continuations or divisionals.
- Method of Use Overlap: Even if a compound is structurally distinct, its intended therapeutic use for a condition claimed in the patent can lead to infringement.
- Formulation Overlap: Patented pharmaceutical compositions could also pose FTO challenges.
The expiration dates of key patents are critical for market entry strategies. U.S. Patent 7,807,708 has an expiration date of October 26, 2027. However, patent term extensions and potential pediatric exclusivity can extend this period.
What is the Status of Compounds Derived from this Patent?
Concert Pharmaceuticals developed CTP-469, a GlyT1 inhibitor based on the patent family of U.S. Patent 7,807,708. CTP-469 was investigated for schizophrenia and cognitive impairment. However, as of recent reports, Concert Pharmaceuticals has shifted its focus, and the development status of CTP-469 and other compounds directly linked to this patent family requires ongoing monitoring of company pipelines and regulatory filings. The continued patent protection offers a window for commercialization, provided clinical development is successful and regulatory hurdles are cleared.
Key Takeaways
U.S. Patent 7,807,708 protects a class of GlyT1 inhibitors and their use in treating neuropsychiatric disorders. The patent claims specific substituted piperidine and piperazine derivatives and their therapeutic applications, primarily for schizophrenia and cognitive deficits. The patent landscape for GlyT1 inhibitors is crowded, requiring careful FTO analysis. The patent expires in October 2027, presenting a potential market entry point for derivatives.
FAQs
-
What is the primary mechanism of action for the compounds claimed in U.S. Patent 7,807,708?
The compounds are designed to inhibit glycine transporter 1 (GlyT1), increasing extracellular glycine levels and thereby enhancing NMDA receptor activity.
-
What is the expiration date of U.S. Patent 7,807,708?
The patent is set to expire on October 26, 2027.
-
What therapeutic areas are targeted by the claims in this patent?
The primary targeted areas are neuropsychiatric disorders, including schizophrenia, bipolar disorder, major depressive disorder, and associated cognitive deficits.
-
Are there any specific chemical structures claimed beyond a general formula?
Yes, the patent includes numerous specific examples of compounds falling within the general Formula I, detailing various substitutions on piperidine and piperazine rings, as well as linker chemistries.
-
What is the significance of the Markush structure in U.S. Patent 7,807,708 for competitors?
The Markush structure defines a broad genus of related compounds. Competitors must ensure their candidate molecules do not fall within the scope of this structure or specific exemplified embodiments to avoid potential infringement.
Cited Sources
[1] Forum Pharmaceuticals Inc. (2010). U.S. Patent 7,807,708: Glycine transporter inhibitors. United States Patent and Trademark Office.
